Saturday, October 3, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleYahoo Finance· February 24, 2026

EXL Reports 2025 Fourth Quarter and Year-End Results; Issues 2026 Guidance

View original at finance.yahoo.com
EXL Reports 2025 Fourth Quarter and Year-End Results; Issues 2026 Guidance EXL 2025Fourth Quarter Revenue of $542.6 Million, up12.7% year-over-year Q4 Diluted EPS (GAAP) of $0.38, up21.8% from $0.31 in Q4 of 2024 Q4 Adjusted Diluted EPS (Non-GAAP) (1) of $0.50, up15.0% from $0.44 in Q4 of 2024 2025 Revenue of $2.09 Bil…
Opening lines of the source · Yahoo Finance · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • 2026 adjusted diluted EPS expected to be $2.14 to $2.19, representing 10% to 12% increase over 2025

    80% confidence
  • Delivered revenue growth of 12.7% and increased adjusted diluted EPS by 15.0% year-over-year in Q4 2025

    80% confidence
  • The $500 million stock repurchase authorization represents confidence in ability to continue growth trajectory and generate significant free cash flow

    80% confidence
  • 2026 revenue expected to be $2.275 billion to $2.315 billion, reflecting 9% to 11% year-over-year growth

    80% confidence
  • EXL's sustained double-digit growth demonstrates the strength of competitive position as a global data and AI company

    80% confidence
  • Investments in building innovative data and AI services and solutions, growing partner ecosystem, and cultivating AI-native talent are driving growth momentum

    80% confidence
  • Closed 2025 with robust growth across business segments, a formidable balance sheet and strong free cash flow

    80% confidence
  • EXL's recognized industry expertise and leadership in embedding AI in clients' businesses are resonating strongly with the market and fueling growth

    80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Pharma Pipeline Catalysts and M&A Heat Up as AI-Designed Drugs Enter the Clinic
Late-September 2026 brought a dense run of clinical readouts: Novo Nordisk's CagriSema data at EASD, Lilly's ADtouch results for EBGLYSS, and Merck's tulisokibart Phase 2b result. Lilly's $2.9B Merida Biosciences acquisition and the 2026-11-14 FDA PDUFA date for ivonescimab sit alongside these as the main deal and regulatory events. AI-designed drugs such as rentosertib, and speculative AI-linked trial ventures such as QAIAx, are moving from hype toward clinical validation. Broader AI-sector regulatory and legal friction (Tesla Cybercab probe, xAI Minnesota ruling, OpenAI lawsuits) shows rising scrutiny that could spill into AI-driven healthcare.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
Apple Inc.
The observation date (2025-12-27) precedes Q1 2026, making it logically impossible to have actual Q1 2026 cash data at that point. Q1 2026 would not end until March 31, 2026. Additionally, the magnitude of the difference ($45.3B vs $132.42) is implausibly large even as a normal quarterly change for Apple. While different fiscal periods can show different values, the timing relationship here suggests a data integrity issue rather than legitimate period-over-period variation.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,329 source documents archived
Query this data → isubstrate.com